Exact Therapeutics AS
OSE:EXTX
Exact Therapeutics AS
Note Receivable
Exact Therapeutics AS
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Exact Therapeutics AS
OSE:EXTX
|
Note Receivable
kr15.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Note Receivable
$32.2m
|
CAGR 3-Years
788%
|
CAGR 5-Years
125%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exact Therapeutics AS
Glance View
EXACT Therapeutics AS is a clinical stage biopharmaceutical company, which engages in the research and development of novel platform for ultrasound mediated therapeutic amplification. The company is headquartered in Oslo, Oslo and currently employs 8 full-time employees. The company went IPO on 2020-07-14. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The firm's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. The company is done through harnessing the power of ultrasound in combination with ACT formulation.
See Also
What is Exact Therapeutics AS's Note Receivable?
Note Receivable
15.2m
NOK
Based on the financial report for Dec 31, 2024, Exact Therapeutics AS's Note Receivable amounts to 15.2m NOK.
